Literature DB >> 18070973

In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.

Doris Hillemann, Sabine Rüsch-Gerdes, Elvira Richter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18070973      PMCID： PMC2224755          DOI： 10.1128/AAC.01189-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

Review 1.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

2.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  Elvira Richter; Sabine Rüsch-Gerdes; Doris Hillemann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

4.  In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides.

Authors:  H Carsenti-Dellamonica; M Galimand; F Vandenbos; C Pradier; P M Roger; B Dunais; M Sabah; G Mancini; P Dellamonica
Journal:  J Antimicrob Chemother       Date:  2005-08-31       Impact factor: 5.790

5.  Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

Authors:  L Xiong; P Kloss; S Douthwaite; N M Andersen; S Swaney; D L Shinabarger; A S Mankin
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

6.  Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations.

Authors:  P Sander; L Belova; Y G Kidan; P Pfister; A S Mankin; E C Böttger
Journal:  Mol Microbiol       Date:  2002-12       Impact factor: 3.501

7.  Linezolid for the treatment of multidrug-resistant tuberculosis.

Authors:  Jesús Fortún; Pilar Martín-Dávila; Enrique Navas; Ma Jesús Pérez-Elías; Javier Cobo; Marta Tato; Elia Gómez-G De la Pedrosa; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  J Antimicrob Chemother       Date:  2005-05-23       Impact factor: 5.790
  7 in total
  34 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

4.  Linezolid for XDR-TB--Final Study Outcomes.

Authors:  Myungsun Lee; Sang Nae Cho; Clifton E Barry; Taeksun Song; Youngran Kim; Ina Jeong
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

5.  Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Authors:  Giovanni Piccaro; Giovanna Poce; Mariangela Biava; Federico Giannoni; Lanfranco Fattorini
Journal:  J Antibiot (Tokyo)       Date:  2015-05-06       Impact factor: 2.649

6.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

7.  rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Authors:  Patrick Beckert; Doris Hillemann; Thomas A Kohl; Jörn Kalinowski; Elvira Richter; Stefan Niemann; Silke Feuerriegel
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 8.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

Review 9.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

10.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.